Linked Hexokinase and Glucose-6-Phosphatase Activities Reflect Grade of Ovarian Malignancy.
FDG
Glucose-6-phosphatase
Hexokinase
Ovarian cancer
Positron emission tomography (PET)
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
11
7
2018
medline:
2
8
2019
entrez:
11
7
2018
Statut:
ppublish
Résumé
Malignant cells exhibit increased rates of aerobic glycolysis. Here, we tested whether the accumulation of fluoro-deoxyglucose-6-phosphate (FDG6P) in ovarian cancers of differential malignancy reflects inversely correlated elevations of hexokinase (HK) and glucose-6-phosphatase (G6Pase) activities. Twenty-nine women with suspected ovarian cancer had positron emission tomography (PET) prior to surgery. From fresh-frozen tissue, we determined the activities of HK and G6Pase, and from the PET images, we determined the tumor maximum standardized uptake value (SUVmax) of 2-deoxy-2-[ The SUVmax of malignant lesions significantly exceeded the SUVmax of benign (p < 0.005) and borderline lesions (p < 0.0005) that did not differ significantly. We found no significant correlation between measured HK or G6Pase activities and histological tumor type or SUVmax except that G6Pase activities were higher in malignant than borderline lesions (p < 0.05). Measured HK and G6Pase activities correlated inversely (p < 0.05). The slopes from the regression lines of the three correlations yielded positively correlated abscissa and ordinate intercepts, designated HK The results distinguished two ovarian cancer phenotypes, one with elevated HK activity and low G6Pase activity, and another with the opposite characteristics.
Identifiants
pubmed: 29987620
doi: 10.1007/s11307-018-1247-2
pii: 10.1007/s11307-018-1247-2
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Hexokinase
EC 2.7.1.1
Glucose-6-Phosphatase
EC 3.1.3.9
Types de publication
Journal Article
Langues
eng
Pagination
375-381Références
J Biol Chem. 1953 Jun;202(2):675-85
pubmed: 13061491
Int J Gynecol Cancer. 2014 Mar;24(3):454-60
pubmed: 24463640
Cancer Lett. 1994 Jul 15;82(1):27-32
pubmed: 7518342
Int J Cancer. 2004 May 10;109(6):926-32
pubmed: 15027127
Biochim Biophys Acta. 2013 Mar;1830(3):2608-18
pubmed: 23266497
Cancer Cell. 2013 Aug 12;24(2):213-228
pubmed: 23911236
Anticancer Agents Med Chem. 2017;17(2):164-170
pubmed: 27804847
Gynecol Oncol. 2010 Mar;116(3):395-8
pubmed: 20042226
Tumour Biol. 2015 Sep;36(10):7649-58
pubmed: 25926381
Oncol Rep. 2010 Apr;23(4):1069-76
pubmed: 20204293
J Cell Physiol. 2005 Mar;202(3):654-62
pubmed: 15389572
J Nucl Med. 2004 Jan;45(1):22-9
pubmed: 14734665
Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):37-45
pubmed: 20717823
Oncol Res Treat. 2014;37(1-2):30-4
pubmed: 24613906
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Int J Gynecol Cancer. 2010 Jan;20(1):110-5
pubmed: 20130510
J Nucl Med. 2013 Apr;54(4):499-506
pubmed: 23471314
Biochim Biophys Acta. 2002 Sep 10;1555(1-3):14-20
pubmed: 12206885
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Mod Pathol. 2005 Feb;18 Suppl 2:S33-50
pubmed: 15761465
Nucl Med Commun. 2011 Jul;32(7):549-53
pubmed: 21407140
Int J Gynecol Cancer. 2012 May;22(4):654-8
pubmed: 22398711
Eur J Radiol. 2011 Apr;78(1):12-20
pubmed: 20116952
Mol Cancer Res. 2014 Nov;12(11):1547-59
pubmed: 25001192
Oncogene. 2006 Aug 7;25(34):4683-96
pubmed: 16892082
Eur J Gynaecol Oncol. 2014;35(5):519-24
pubmed: 25423696
Front Neuroenergetics. 2013 Mar 27;5:2
pubmed: 23543638
Acta Med Okayama. 2012;66(1):53-60
pubmed: 22358139
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Onkologie. 2013;36(4):169-74
pubmed: 23548964
Biochem J. 2002 Mar 15;362(Pt 3):513-32
pubmed: 11879177
Int J Gynaecol Obstet. 2008 Aug;102(2):124-7
pubmed: 18423470
J Cereb Blood Flow Metab. 2012 Dec;32(12):2146-52
pubmed: 22929437